{"nctId":"NCT01139762","briefTitle":"A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms","startDateStruct":{"date":"2010-09"},"conditions":["Benign Prostatic Hyperplasia","Enlarged Prostate"],"count":696,"armGroups":[{"label":"Tadalafil","type":"EXPERIMENTAL","interventionNames":["Drug: Tadalafil","Drug: Finasteride"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Finasteride"]}],"interventions":[{"name":"Tadalafil","otherNames":["Cialis","LY#450190"]},{"name":"Placebo","otherNames":[]},{"name":"Finasteride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have not taken the following treatments within the indicated duration and agree not to use at any time during the study:\n\n  * All other Benign Prostatic Hyperplasia (BPH) therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.\n  * Overactive bladder therapy (including antimuscarinics) for at least 4 weeks prior to receiving study medication.\n  * Erectile Dysfunction therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.\n  * Finasteride or dutasteride use at any time.\n* Have bladder outlet obstruction as defined by a urinary peak flow rate (Qmax) of greater than or equal to 4 and less than or equal to 15 milliliters (mL)/second before receiving study drug.\n* Have prostate enlargement measured by ultrasound at screening.\n\nExclusion Criteria:\n\n* Have prostate cancer, are being treated for cancer or have clinical evidence of prostate cancer \\[Prostate-specific antigen (PSA) greater than 10 nanograms/milliliter (ng/mL) at the start of study\\].\n* Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).\n* Have problems with kidneys, liver, or nervous system\n* Have uncontrolled diabetes\n* Have had a stroke or a significant injury to brain or spinal cord.\n* Have scheduled or planned surgery during the course of the study.","healthyVolunteers":false,"sex":"MALE","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks","description":"The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.18","spread":"0.32"},{"groupId":"OG001","value":"-3.76","spread":"0.32"}]}]}]},{"type":"SECONDARY","title":"Change in Total International Prostate Symptom Score (IPSS) From Baseline to 4 and 26 Weeks","description":"The International Prostate Symptom Score (IPSS) is a rating scale for severity of lower urinary tract symptoms (LUTS). The IPSS has a 7-component questionnaire. Each question is scored on a scale from 0 (none/no symptoms) to 5 (frequent symptoms), for a total score range of 0 to 35. Higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.95","spread":"0.29"},{"groupId":"OG001","value":"-2.29","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.51","spread":"0.33"},{"groupId":"OG001","value":"-4.47","spread":"0.33"}]}]}]},{"type":"SECONDARY","title":"Change in International Prostate Symptom Score (IPSS) Subscores Index From Baseline to 4, 12, and 26 Weeks","description":"IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the 7-component IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore range from 0 to 15. IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score range from 0 to 20. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.27","spread":"0.14"},{"groupId":"OG001","value":"-0.76","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.74","spread":"0.14"},{"groupId":"OG001","value":"-1.34","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","spread":"0.15"},{"groupId":"OG001","value":"-1.66","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.65","spread":"0.19"},{"groupId":"OG001","value":"-1.47","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.41","spread":"0.21"},{"groupId":"OG001","value":"-2.37","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.50","spread":"0.22"},{"groupId":"OG001","value":"-2.77","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change in International Prostate Symptom Score (IPSS) Quality of Life Index From Baseline to 4, 12, and 26 Weeks","description":"IPSS Quality of Life Index assesses participant response to the following question: \"If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?\" Response options are Delighted (0); Pleased (1); Mostly satisfied (2); Mixed-about equally satisfied and dissatisfied (3); Mostly dissatisfied (4); Unhappy (5); Terrible (6), with a total range of 0-6. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline total IPSS, and visit-by-treatment interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"0.07"},{"groupId":"OG001","value":"-0.32","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"0.07"},{"groupId":"OG001","value":"-0.76","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.10","spread":"0.08"},{"groupId":"OG001","value":"-0.92","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change in International Index of Erectile Function (IIEF) - Erectile Function Domain Scores From Baseline to 4, 12, and 26 Weeks","description":"Self-reported erectile function over the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 is scored 1 (very low confidence) to 5 (very high confidence), for a total score ranging from 1 to 30. Higher scores represent better erectile function. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.71","spread":"0.50"},{"groupId":"OG001","value":"-1.14","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.71","spread":"0.56"},{"groupId":"OG001","value":"0.63","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.71","spread":"0.57"},{"groupId":"OG001","value":"-0.02","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Change in International Index of Erectile Function (IIEF) - Overall Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks","description":"Self-reported overall satisfaction over the past 4 weeks. IIEF-Overall Satisfaction is the sum of Questions 13 and 14 of IIEF questionnaire. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher total scores indicate higher satisfaction. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"0.15"},{"groupId":"OG001","value":"-0.10","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"0.16"},{"groupId":"OG001","value":"0.31","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":"0.17"},{"groupId":"OG001","value":"0.40","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Change in International Index of Erectile Function (IIEF) - Intercourse Satisfaction Domain Scores From Baseline to 4, 12, and 26 Weeks","description":"Self-reported intercourse satisfaction over the past 4 weeks. IIEF-intercourse satisfaction is the sum of Questions 6, 7 and 8 of the IIEF. Scores range from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions of 0 to 15. Higher total scores indicate higher satisfaction. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":"0.24"},{"groupId":"OG001","value":"-0.46","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"0.26"},{"groupId":"OG001","value":"0.08","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":"0.27"},{"groupId":"OG001","value":"-0.26","spread":"0.28"}]}]}]},{"type":"SECONDARY","title":"Change in International Index of Erectile Function (IIEF) - Orgasmic Function Domain Scores From Baseline to 4, 12, and 26 Weeks","description":"Orgasmic Function domain scores is the sum of Questions 9 and 10 from the IIEF questionnaire. Scores range from 0 (low/no orgasm) to 5 (high orgasm) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Higher total scores indicate higher orgasm. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"0.22"},{"groupId":"OG001","value":"-0.63","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"0.23"},{"groupId":"OG001","value":"0.18","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.24"},{"groupId":"OG001","value":"-0.18","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Change in International Index of Erectile Function (IIEF) - Sexual Desire Domain Scores From Baseline to 4, 12, and 26 Weeks","description":"Sexual desire domain scores is the sum of Questions 11 and 12 from the IIEF questionnaire. Scores range from 1 (low/no desire) to 5 (high desire) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher total scores indicate higher desire. Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":"0.12"},{"groupId":"OG001","value":"-0.47","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.13"},{"groupId":"OG001","value":"-0.23","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"0.13"},{"groupId":"OG001","value":"-0.05","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Patient Global Impression of Improvement (PGI-I) at 26 Weeks","description":"Patient Global Impression of Improvement (PGI-I) measures the participant's perception of improvement at the time of assessment compared with the start of treatment. Number of participants is reported by the categorized score ranging from 1 (very much better) to 7 (very much worse).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 26 Weeks","description":"The TSS-BPH was a validated participant-rated instrument that measured participant satisfaction with treatment based on a 13-item questionnaire. It consists of 10 items on a Likert-like scale with scores ranging from 1 (higher satisfaction) to 5 (lower satisfaction), 1 item with score ranging from 0 (higher satisfaction) to 5 (lower satisfaction), and 2 yes/no questions. The mean score for each participant ranges from 0.9 (higher satisfaction) to 5.0 (lower satisfaction). Data presented are the average of mean scores for each treatment group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"0.63"},{"groupId":"OG001","value":"2.1","spread":"0.66"}]}]}]},{"type":"SECONDARY","title":"Clinician Global Impression of Improvement (CGI-I) at 26 Weeks","description":"Clinician Global Impression of Improvement (CGI-I) measures clinician's perception of participant improvement at the time of assessment compared with the start of treatment. Number of participants is reported by the categorized score ranging from 1 (very much better) to 7 (very much worse).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Post Void Residual (PVR) Volume From Baseline to 26 Weeks","description":"Postvoid Residual Volume (PVR) is determined using a portable, calibrated ultrasound device. It consists of the average of a minimum of 3 scans where the residual bladder volume was calculated by averaging the most accurate of the 3 imaging attempts.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.8","spread":"73.08"},{"groupId":"OG001","value":"-23.1","spread":"66.15"}]}]}]},{"type":"SECONDARY","title":"Change in International Index of Erectile Function (IIEF) Question 3 and 4 Scores From Baseline to 4, 12, and 26 Weeks","description":"IIEF Question 3 asks how often a participant was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). IIEF Question 4 asks whether/how often a participant was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes treatment, region, visit, baseline IIEF, and visit-by-treatment interaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42","spread":"0.09"},{"groupId":"OG001","value":"-0.32","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"0.09"},{"groupId":"OG001","value":"0.04","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"0.10"},{"groupId":"OG001","value":"-0.07","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"0.09"},{"groupId":"OG001","value":"-0.21","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.74","spread":"0.09"},{"groupId":"OG001","value":"0.13","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"0.10"},{"groupId":"OG001","value":"0.06","spread":"0.10"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":1070},"commonTop":["Headache","Back pain","Influenza","Nasopharyngitis","Dyspepsia"]}}}